Onyia Jude's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Jul 7, 2025
- Accession no.
- 0000914475-25-000149
- Filed
- Jul 7, 2025
- Trade date
- Jul 2, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.65M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Onyia JudeCIK 0001894425 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2025 | Common Stock | MOption exerciseAcquired | +20,362 | $84.74 | +$1,725,475.88 | 38,651 | Direct | |
| Jul 2, 2025 | Common Stock | SSaleDisposed | −20,362 | $130.13 | −$2,649,707.06 | 18,289 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2025 | Common Stock | MOption exerciseDisposed | −20,362 | $0.00 | $0 | 95,087 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.